DARE stock sentiment todayDare Bioscience Inc
Sentiment verdict
Gossip first, financials second — NEUTRAL at 65% confidence.
Last updated · cached analysis, refreshes periodically
DARE
Dare Bioscience IncA high-risk micro-cap biotech with a validated commercial product but faces significant liquidity challenges and dilution risks.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for DARE. Not financial advice.
Price · last 12 months
Gossip
The narrative is split between optimism over its FDA-approved product XACIATO and frustration regarding the stock's penny-stock status. Investors are hyper-focused on non-dilutive funding rumors and the potential for royalty monetization.
- ·FDA approval of XACIATO (bacterial vaginosis)
- ·Partnership with Organon for commercialization
- ·Concerns over potential NASDAQ delisting due to price
- ·Anticipation of Phase 3 data for Ovaprene
Financial
Typical early-commercial biotech profile: high cash burn, limited revenue, and a reliance on capital raises. While they have secured some non-dilutive grants (Bill & Melinda Gates Foundation), the balance sheet remains fragile.
- ·Negative EPS (recurring losses)
- ·High cash burn relative to $0.70 share price
- ·Low institutional ownership
- ·Market cap hovering near micro-cap thresholds
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Strong conviction — insiders and patient capital are backing this.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Dilution from secondary offerings to fund operations
- ·Slow commercial uptake of XACIATO by partner Organon
- ·Clinical trial failure for pipeline candidates (Ovaprene, Sildenafil Cream)
- ·Regulatory hurdles for women's health products
Peer temperature
How direct competitors stack up against DARE right now.
- COLDEVFMEvofem Biosciences
COLDER — struggling with deeper debt obligations and recent delisting from major exchanges despite having Phexxi on market.
See full analysis → - NEUTRALAGTCApplied Genetic Technologies
NEUTRAL — similar cash-to-burn ratios but lacks DARE's diversified late-stage women's health focus.
See full analysis → - HOTORGNOrganon & Co.
HOTTER — the commercial giant and DARE partner with massive cash flow and a stable dividend, representing far less risk.
See full analysis →
- DARE-18.0%
- EVFM-14.3%
- AGTC—
- ORGN—
Analyst price target
Consensus average of 3 analysts · median 8.00
Source: StockAnalysis.com · updated 2026-10-26
AI-generated analysis for informational purposes only. Not financial advice.